Management of pT3, Gleason 7 Prostate Cancer After Radical Prostatectomy
Introduction to Guideline Recommendations
- The National Comprehensive Cancer Network (NCCN) recommends ADT as a Category 1 recommendation only when positive lymph nodes are documented at or after radical prostatectomy 1, 2, 3
- One randomized trial demonstrated that immediate ADT in men with pathologically confirmed positive nodes resulted in significantly improved overall survival compared to delayed ADT, with a strength of evidence considered high 4, 5
Adjuvant Radiation Therapy
- Adjuvant radiation therapy is the evidence-based intervention for adverse pathologic features like pT3 disease, with a 5-year biochemical progression-free survival of 72% with RT versus 54% with observation (HR 0.53), based on moderate to high quality evidence 1, 2, 3
- Adjuvant RT should be delivered within 1 year of surgery and is particularly beneficial for patients with positive surgical margins, seminal vesicle invasion, extracapsular extension, or a PSA doubling time <9 months, according to NCCN guidelines 1, 2, 3
Risk Stratification and Treatment Selection
- The NCCN guidelines recommend pelvic lymph node dissection when predicted probability of lymph node metastasis is ≥2%, which would apply to most pT3, Gleason 7 cases, based on moderate quality evidence 5, 6
- Primary recommendation is adjuvant radiation therapy to the prostate bed, with a dose of at least 70 Gy using 3D conformal techniques, and timing within 1 year of surgery, ideally when PSA is low or undetectable, according to NCCN guidelines 1, 3, 6
Important Considerations
- ADT causes significant quality of life impacts, including sexual dysfunction, hot flashes, osteoporosis, metabolic syndrome, and cardiovascular risks, with a strength of evidence considered high 4, 5, 3
- Without documented nodal disease, the risk-benefit ratio does not favor ADT, based on moderate to high quality evidence 1, 3